CytoSorbents Corporation (CTSO)

[dah174174]

Email from Dr. Chan
I cannot comment on the share price except to say that similar companies often are "bought on the rumor and sold on the news" and some may have been disappointed that we did not discuss hemoglobin numbers. That said, as I have stated publicly before, know that the main reason the FDA wanted this safety and feasibility study was to demonstrate safety, which we have done. As I said in the last earnings call, the goal of the free hemoglobin was to demonstrate that our specific target population had high levels of free hemoglobin and that we could do something about it. That said, there are many cooks in the kitchen on this study and many physicians have input. We learned that many do not believe that a release of such data in a press release before meeting with the FDA is appropriate. Also many people involved in the trial and on our advisory board still need to review the data. Because of this, there was no hemoglobin data in this PR. But we had committed to releasing topline data this week and have released the most important data. In terms of hemoglobin, I think Dr. Bartlett would not say "promising" if he didn't think so.

Best,
Phillip